TG Therapeutics Inc (NASDAQ:TGTX) has earned a consensus rating of “Buy” from the nine brokerages that are currently covering the firm, Marketbeat.com reports. Three research analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $15.67.
A number of brokerages have commented on TGTX. BidaskClub downgraded shares of TG Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, May 14th. Cantor Fitzgerald reiterated a “buy” rating and set a $17.00 price objective on shares of TG Therapeutics in a research note on Monday, May 13th. HC Wainwright reiterated a “buy” rating and set a $20.00 price objective on shares of TG Therapeutics in a research note on Friday, April 12th. Zacks Investment Research downgraded shares of TG Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, April 6th. Finally, ValuEngine upgraded shares of TG Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, March 29th.
Shares of TGTX stock traded up $0.23 during trading hours on Thursday, hitting $6.98. 57,364 shares of the company’s stock were exchanged, compared to its average volume of 2,027,251. The company has a debt-to-equity ratio of 1.89, a quick ratio of 2.03 and a current ratio of 1.72. TG Therapeutics has a 52 week low of $3.32 and a 52 week high of $16.00.
TG Therapeutics (NASDAQ:TGTX) last announced its earnings results on Friday, May 10th. The biopharmaceutical company reported ($0.43) EPS for the quarter, topping the consensus estimate of ($0.44) by $0.01. The company had revenue of $0.04 million for the quarter, compared to analysts’ expectations of $0.04 million. TG Therapeutics had a negative return on equity of 309.17% and a negative net margin of 99,471.43%. As a group, analysts predict that TG Therapeutics will post -1.61 earnings per share for the current fiscal year.
Several hedge funds and other institutional investors have recently made changes to their positions in TGTX. Great Point Partners LLC raised its stake in TG Therapeutics by 53.8% during the fourth quarter. Great Point Partners LLC now owns 3,000,000 shares of the biopharmaceutical company’s stock worth $12,300,000 after purchasing an additional 1,050,000 shares during the period. Opaleye Management Inc. grew its holdings in shares of TG Therapeutics by 148.4% in the first quarter. Opaleye Management Inc. now owns 1,366,062 shares of the biopharmaceutical company’s stock valued at $10,983,000 after purchasing an additional 816,062 shares in the last quarter. Two Sigma Investments LP grew its holdings in shares of TG Therapeutics by 312.9% in the fourth quarter. Two Sigma Investments LP now owns 769,011 shares of the biopharmaceutical company’s stock valued at $3,153,000 after purchasing an additional 582,771 shares in the last quarter. venBio Select Advisor LLC grew its holdings in shares of TG Therapeutics by 13.1% in the fourth quarter. venBio Select Advisor LLC now owns 4,750,000 shares of the biopharmaceutical company’s stock valued at $19,475,000 after purchasing an additional 549,969 shares in the last quarter. Finally, Renaissance Technologies LLC acquired a new position in shares of TG Therapeutics in the third quarter valued at approximately $1,974,000. Institutional investors and hedge funds own 55.26% of the company’s stock.
TG Therapeutics Company Profile
TG Therapeutics, Inc, a biopharmaceutical company, engages in developing and delivering medicines for patients with chronic lymphocytic leukemia (CLL), non-Hodgkin's Lymphoma (NHL), and Multiple Sclerosis (MS). It develops a robust B-cell directed research and development platform for identification of key B-cell pathways of interest and rapid clinical testing.
Featured Story: Trading Stocks – What are percentage gainers?
Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.